

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

\*  $p < 0.05$  VERSUS NO TREATMENT

# Experimental Protocol

5TGM1

Day 0 1 7 14 21 28

28

anti $\alpha$ 4Ab 200ug i.p.  
100ug i.p.

100ug i.p.

Melphalan

100ug i.p.

•lgG<sub>2</sub>  
•Histomorphometric  
analysis of bones

Figure 7

# Serum IgG<sub>2</sub> levels in 5TGM1-bearing mice




Figure 8

# Tumor Volume in Bone

Treatment/no treatment (%)  
 $n=6-12$




Figure 9

EFFECT OF PS/2 mAb TREATMENT  
ON SPLEEN WEIGHT




Figure 10

EFFECT OF PS/2 TREATMENT ON SPLENOCYTES  
IN MICE WITH 5TGM1 MYELOMA





Figure 11

# EFFECT OF PS/2 mAb TREATMENT ON SPLEENOCYTE FACS PROFILE


## DISEASE FREE



File: do111700.077      Acquisition Date: 17-Nov-00  
 Gate: G1      Gated Events: 9624  
 Total Events: 10707      Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	9499	98.70	88.72	37.11	1120.67
UR	3	0.03	0.03	5084.96	773.52
LL	122	1.27	1.14	31.88	11.09
LR	0	0.00	0.00	***	***


## UNTREATED



File: do111700.100      Acquisition Date: 17-Nov-00  
 Gate: G1      Gated Events: 9526  
 Total Events: 11100      Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4959	52.06	44.68	84.30	1023.41
UR	1388	14.57	12.50	2377.81	704.20
LL	2163	22.71	19.49	50.53	6.64
LR	1016	10.67	9.15	3619.03	4.05


## PS/2 TREATED



File: do111700.120      Acquisition Date: 17-Nov-00  
 Gate: G1      Gated Events: 9561  
 Total Events: 10934      Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	7868	82.29	71.96	58.00	1139.33
UR	310	3.24	2.84	1922.82	897.47
LL	1171	12.25	10.71	42.10	8.17
LR	212	2.22	1.94	3153.17	3.62

## rat IgG2b TREATED



File: do111700.137      Acquisition Date: 17-Nov-00  
 Gate: G1      Gated Events: 9595  
 Total Events: 10970      Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4910	51.17	44.76	84.95	975.19
UR	1384	14.42	12.62	1937.36	694.49
LL	1704	17.76	15.53	48.67	7.00
LR	1597	16.64	14.56	3286.15	2.68

Figure 12

EFFECT OF PS/2 mAb TREATMENT ON  
SPEEN TUMOR BURDEN




Figure 13

EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS  
IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN  
mIgG2b POSITIVE CELLS




Figure 15

EFFECT OF PS/2 mAb TREATMENT  
ON 5TGM1 CELLS IN THE BLOOD




Figure 16

## EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

EFFECT OF PS/2 mAb ON  
CIRCULATION mIgG2b LEVELS




Figure 18

C57/Bl Kallwaj MULTIPLE MYELOMA MODEL  
ACUTE TREATMENT PROTOCOLS




Figure 19

EFFECT OF PS/2 TREATMENT ON IgG2b POSITIVE CELLS  
ACUTE TREATMENT MODEL




Figure 20

EFFECT OF ANTI VLA-4 ANTIBODY PS/2  
ON TUMOR BURDEN IN SPLEEN




Figure 21

## EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

## EFFECT OF 6 DAYS OF PS/2 TREATMENT ON BONE MARROW CELLS





Figure 23

C57/BLK1LwRaj MODEL OF MULTIPLE MYELOMA  
COMBINATION TREATMENT WITH PS/2 AND MELPAHLAN



5TGMI CELLS (1E6) WERE INJECTED (I.V.) ON DAY 0  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27

GROUPS N=3/GROUP

DISEASE FREE CONTROL  
UNTREATED MYELOMA CONTROL  
MELPAHLAN TREATMENT -- 100 MICROGRAMS/INJECTION  
PS/2 TREATMENT -- 100 MICROGRAMS/INJECTION  
MELPAHLAN AND PS/2  
MELPAHLAN AND rIgG2b ISOTYPE CONTROL

Figure 24

## EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

### EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27




Figure 26

## EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27





Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detect d	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 $\mu$ g/ml	none detected
13-melphalan+PS/2	none detected	none detected

**Figure 28**

C57/BlKaLwRaj MODEL OF MULTIPLE MYELOMA  
 PS/2 AND ANTI VLA4 SMALL MOLECULE  
 LONG TERM TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0  
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP  
 DISEASE FREE CONTROL  
 UNTREATED MYELOMA CONTROL  
 PS/2 --100 micrograms/injection  
 Sm. Mol. 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg  
 Sm. Mol. 9257 CONTROL-- 3 mg/kg

Figure 29

# EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

## EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

C57/B1K/wRaj MODEL OF MULTIPLE MYELOMA  
PS/2 AND ANTI VLA4 SMALL MOLECULE  
ACUTE TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0  
PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20  
SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP  
DISEASE FREE CONTROL  
UNTREATED MYELOMA CONTROL  
PS/2 --100 micrograms/injection  
8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg  
9257 CONTROL -- 3 mg/kg

Figure 32

### EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS




Figure 33

## EFFECT OF ACUTE TREATMENT ON TUMOR BUREN




Figure 34

## Experimental Protocol




Figure 35

## Inhibition of Hindleg Paralysis




Figure 36